Source: CureToday articles
Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemo.
Recent Content
- DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy
- NCCN Flash Update: Changes to Colon Cancer Guidelines, Version 3.2025
- Commitment to Patients Is Driven by a Lasting Promise
- AAN 2025: Low-Sodium Oxybate Improves Sleep Quality, Daily Functioning in Narcolepsy, Idiopathic Hypersomnia
- Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care
- New Options for ER+ Breast Cancer Spotlighted at Patient Event
- Asembia’s AXS25 Summit: Must-See Sessions, Expert Interviews as Specialty Pharmacy Gathers
- A Digital Detox for the Soul with Lynch Syndrome
- NCPA Urges DOGE to Examine PBMs for Waste, Fraud, and Abuse
- Decipher Prostate Test Now Available for Metastatic Prostate Cancer